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Introduction: Bacterial meningitis among critically ill adult patients remains associated with both high mortality
and frequent, persistent disability. Vancomycin was added to treatment with a third-generation cephalosporin as
recommended by French national guidelines. Because animal model studies had suggested interest in the use of
rifampin for treatment of bacterial meningitis, and after the introduction of early corticosteroid therapy (in 2002),
there was a trend toward increasing rifampin use for intensive care unit (ICU) patients. The aim of this article is to
report on this practice.
Methods: Five ICUs participated in the study. Baseline characteristics and treatment data were retrospectively
collected from charts of patients admitted with a diagnosis of acute bacterial meningitis during a 5-year period
(2004–2008). The ICU mortality was the main outcome measure; Glasgow Outcome Scale and 3-month mortality
were also assessed.
Results: One hundred fifty-seven patients were included. Streptococcus pneumoniae and Neisseria meningitidis were
the most prevalent causative microorganisms. The ICU mortality rate was 15 %. High doses of a cephalosporin were
the most prevalent initial antimicrobial treatment. The delay between admission and administration of the first
antibiotic dose was correlated with ICU mortality. Rifampin was used with a cephalosporin for 32 patients (ranging
from 8 % of the cohort for 2004 to 30 % in 2008). Administration of rifampin within the first 24 h of hospitalization
could be associated with a lower ICU survival. Statistical association between such an early rifampin treatment and
ICU mortality reached significance only for patients with pneumococcal meningitis (p=0.031) in univariate analysis,
but not in the logistic model.
Conclusions: We report on the role of rifampin use for patients with community-acquired meningitis, and the
results of this study suggest that this practice may be associated with lower mortality in the ICU. Nevertheless, the
only independent predictors of ICU mortality were organ failure and pneumococcal infection. Further studies are
required to confirm these results and to explain how rifampin use would reduce mortality.Introduction
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this article, unless otherwise stated.infections [1–8]. Coadministration of corticosteroids has
made major progress in the last decade. Indeed, in 2002, de
Gans and van de Beek demonstrated that early adminis-
tration of dexamethasone improves both mortality and
neurological outcome [9]. However, such a use of corti-
costeroids yielded many questions [8, 10]. What about
antibiotic diffusion into the cerebrospinal fluid (CSF)?
Would it be decreased?
French guidelines added a second antibiotic to a ceph-
alosporin for those patients at risk of contracting a
penicillin-resistant or less susceptible strain or for clinicallyarticle is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
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to the intensive care unit (ICU) were generally treated with
a third-generation cephalosporin and vancomycin. After
widespread steroid use, French physicians wondered
whether the efficacy of vancomycin would be maintained
[12, 13]. At the same time, other antibiotics, such as
fosfomycin and rifampin, were shown to have pharma-
cokinetic and pharmacodynamic properties that could
make them good candidates for the treatment of men-
ingeal infections [14]. Using rifampin appeared at that
time to be an interesting concept because previous ex-
perimental studies in animal models had suggested that
rifampin reduces the inflammatory response caused by
β-lactam–induced bacterial lysis [15, 16].
The aim of this report is to describe a cohort of adult
patients admitted to the ICU for community-acquired
bacterial meningitis, with a specific focus on rifampin use.
Methods
Study design/center characteristics
This study was multicentered and retrospective. Five
French ICUs participated. Four of them are teaching
medical ICUs: Nantes, Rouen, Paris, and Kremlin-Bicêtre.
The fifth, Roanne, is a general medicosurgical ICU. During
the study period, these ICUs had, respectively, 20, 20, 18,
15, and 16 ventilated beds. Yearly admissions to the ICU
during the study period ranged from 650 to 1100.
Inclusion criteria
All sequential patients admitted to the ICUs were
assessed for inclusion in the study. Adult patients were
included if they met the following criteria:
 Admission to one of the five participating ICUs
during the 5-year period from 1 January 2004
through 31 December 2008
 Admission for community-acquired bacterial
meningitis
The patients’ clinical presentation had to be consistent
with this diagnosis. CSF samples had to show pleiocytosis
(white cell count >5/mm3). In those patients with an obvi-
ous clinicobiological diagnosis but a contraindication to
lumbar puncture (e.g., major coagulation abnormalities),
missing CSF analysis was permitted.
Exclusion criteria were nosocomial meningitis, tubercu-
losis diagnosis, viral or parasitic etiology, cerebral abscess,
or secondary localizations of endocarditis.
Data collection
Patients’ baseline characteristics
The following data were taken from charts: demographic
data, comorbidities, clinical characteristics at emergency
department and ICU admission, and severity measuressuch as the Simplified Acute Physiology Score II
(SAPS II) [17] or the Logistic Organ Dysfunction
(LOD) system [18].
Outcome
The main outcome assessment was ICU mortality, but
3-month mortality and Glasgow Outcome Scale (GOS)
score were also recorded when possible. The GOS is
widely used to assess disability after severe brain damage
or after medical conditions such as meningeal infections.
In brief, it has five categories: dead, vegetative, severely
disabled, moderately disabled, and good recovery [19].
Microbiological data
CSF characteristics were analyzed. Bacterial identifica-
tion could also be derived from other samples, such as
blood cultures or skin cultures.
Antimicrobial susceptibility was tested according to
French national guidelines [20] and in accordance with
the European Committee on Antimicrobial Susceptibility
Testing. Thus, minimal inhibitory concentrations (MICs)
for Streptococcus pneumoniae were as follows:
1. Penicillin: susceptible, MIC ≤0.06 mg/ml; intermediate,
MIC 0.1–1 mg/ml; and resistant, MIC >1 mg/ml
2. Amoxicillin: susceptible, MIC ≤0.5 mg/ml;
intermediate, MIC 1–2 mg/ml; and resistant,
MIC >2 mg/ml
3. Third-generation cephalosporins (cefotaxime or
ceftriaxone): susceptible, MIC ≤0.5 mg/ml;
intermediate, MIC 1–2 mg/ml; and resistant,
MIC >2 mg/ml
Treatment data
Antibiotic regimens were described according to type of
antibiotics, doses, eventual combination, and timing of
administration. Steroid administration was also investi-
gated. Data concerning antibiotic tolerance were also
documented from patients’ charts. Considered adverse
events (AEs) were those that were sufficiently serious for
clinicians to be mentioned in the ICU hospitalization
report.
Statistical analysis
Results were expressed as mean ± standard deviation or
median with interquartile range (IQR). The categorical
data were presented as percentages. These data were
compared with the Fisher’s exact test, and continuous
data were compared with Student’s t test when normality
criteria (Kolmogorov-Smirnov test) were fulfilled or with
non-parametric tests in case of non-normality. Missing
data were treated in the simplest approach: analyses
were performed on only the completed cases. Missing
data were excluded from the analysis.


















Fig. 1 Correlation between time of antibiotic administration and
















Fig. 2 The proportion of patients treated with vancomycin, rifampin,
and corticosteroids between 2004 and 2008
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vestigate the link between different variables and ICU
mortality, a binary logistic regression model was used.
Variables with a p value <0.20 in univariate analysis were
entered into the models. The final model was kept because
of its ability to best predict the outcome, maximizing the
likelihood ratio. The highest Nagelkerke’s R2 then obtained
is presented with the final model. Use of a Cox model
would have been an option. However, follow-up times
were highly variable. This made us prefer a logistic
regression model.
Analyses with a p value <0.05 were considered statistically
significant. The analysis was carried out using IBM SPSS
Statistics version 19 software (IBM, Armonk, NY, USA).
Ethical approval
The protocol was approved by the ethics committee of
the French Intensive Care Society, Société de Réanimation
de Langue Française. Because of the retrospective nature
of this study and according to French and European laws,
no informed consent was required.
Results
More than 20,000 patients were admitted to the 5 par-
ticipating ICUs during the 5-year study period. One
hundred fifty-seven patients (1.2 % of the ICU admis-
sions) were included in this study. The patients’ mean
age was 45±20 years. Ninety-seven (62 %) were men.
The following predisposing conditions were found:
alcohol use disorders (n=18; 11 %), previous episode of
meningitis (n=8; 5 %), HIV infection (n=8; 5 %), and
asplenia (n=6; 4 %). At the ICU admission, the mean
Glasgow Coma Scale score was 11±4, and the mean
SAPS II was 33±21. Assessed in the LOD system, the
neurologic system was the most frequently involved
organ dysfunction at ICU admission (60 %), whereas
pulmonary, hematologic, cardiovascular, and renal failures
were present in 44 %, 42 %, 37 %, and 24 % of the cases,
respectively. No patient had liver failure. At admission, the
criteria for severe sepsis or septic shock were fulfilled for
84 % of the patients. Mechanical ventilation was needed
for 44 % of them.
Median length of ICU stay was 4 days (IQR 2–7). ICU
mortality was 15 %, and 3-month mortality was 22 %.
GOS scores were available for 120 patients with a me-
dian follow-up period of 231 days. Three months after
admission, 24 patients were dead (GOS 1), none were in
a persistent vegetative state (GOS 2), and 4 had severe
disability (GOS 3). Ninety patients (76 %) were consid-
ered to have a favorable outcome: 7 had moderate dis-
ability (GOS 4), and 85 had a good recovery (GOS 5).
No difference was observed between centers (no
center effect for demographic data, microbiological
data, or treatment).Microbiological data
Lumbar puncture was contraindicated in four patients
owing to coagulation disorders. For 30 of 153 patients,
CSF culture was sterile. Seven of those had a positive
microscopic result. Microbiological data were also available
from blood (n=25) or skin cultures (n=2) or from molecular
techniques (PCR on CSF; n=21). Overall, microbiological
documentation was available for 136 patients (87 %). The
main causative bacteria were S. pneumoniae (56 %) and
Neisseria meningitidis (32 %). The results are shown in
Additional file 1: Figure S1. Among S. pneumoniae strains,
susceptibility to β-lactams was as follows: (1) intermediate
or resistant to penicillin, 48 %; (2) intermediate or resistant
to amoxicillin, 11 %; and (3) intermediate or resistant to
third-generation cephalosporins, 7 %. The rate of penicillin
non-susceptible pneumococcal strains was 60 % in 2004.
That rate dropped to 40 % in 2006 and remained around
that level until 2008.
Therapeutic measures
The mean time between hospital admission and first
antibiotic administration was 2.5 h (IQR 1.0-6.1). There
was lower ICU mortality for patients with earlier
Bretonnière et al. Critical Care  (2015) 19:303 Page 4 of 9antibiotic treatment (Fig. 1). Among ICU survivors, me-
dian time (IQR) between hospital admission and first
antibiotic administration was 1.6 (0.6–3.7) versus 3.8
(2.1–5.5) for non-survivors (p=0.003). An antibiotic
combination was the initial prescription for 119 patients
(76 %). A third-generation cephalosporin (89 %) was
generally used with vancomycin (68 %) or rifampin (23
%). During the study period, vancomycin use decreased
and rifampin use became more frequent. Corticosteroid
therapy was administered to 105 patients (67 %). The
treatment consisted of a conventional treatment with
dexamethasone for 91 patients and low-dose hydrocorti-
sone for septic shock for 12 others. Two received anotherTable 1 Comparison of patient characteristics, severity at ICU admis







Alcohol use disorder 4
Asplenia 1
HIV infection 1
Severity at ICU admission
Glasgow Coma Scale score 1
Mechanical ventilation 1










CSF white cell count/mm3 1
CSF protein rate, g/L 3
Positive direct examination of CSF 2
Streptococcus pneumoniae as causative bacterium 2
Penicillin non-susceptible isolates 1
Neisseria meningitidis as causative bacterium 5
Therapeutic measures
Time between hospital admission and first dose of antibiotic (h) 2
Treatment with corticosteroids during hospitalization 2
SAPS II Simplified Acute Physiology Score II, CSF cerebrospinal fluid, LOD Logistic Or
Data are proportion of patients or median values [interquartile range]
p Values <0.2 are detailed. p Values <0.05 were considered significant (bold)regimen. The rate of steroid therapy was stable during the
study period. Figure 2 summarizes these results.
For pneumococcal infections, an initial combination of
antibiotics was more frequently used (95 % vs. 58 %;
p<0.0001). Corticosteroids were also more frequently
administered (82 % vs. 53 %; p<0.001).
Rifampin use
Among 157 patients, 32 (20 %) received rifampin. Rifampin
use was equally distributed in all five ICUs. It was never
prescribed as a monotherapy, but always in addition to a
third-generation cephalosporin. It was administered within
the first 24 h of hospitalization for 19 patients (59 %),sion, microbiological data, and therapeutic measures between
rial meningitis (n=157)
ifampin No rifampin p
Value=32 n=125
IQR IQR
1.4 [28.7–59.4] 51.1 [34.6–69.3] 0.087
2/32 37.5 % 48/125 38.4 % NS
/32 18.8 % 23/125 18.4 % NS
/31 12.9 % 14/124 11.3 % NS
/32 3.1 % 5/124 4.0 % NS
/32 3.1 % 7/124 5.6 % NS
1 [8–14] 12 [7–15] NS
1/25 44.0 % 49/111 44.1 % NS
1/25 84.0 % 94/111 84.7 % NS
9 [16–43] 30 [20–48] NS
4/25 56.0 % 68/111 61.3 % NS
1/25 44.0 % 49/111 44.1 % NS
1/25 44.0 % 46/111 41.4 % NS
2/25 48.0 % 38/111 34.2 % NS
/25 20.0 % 27/111 24.3 % NS
–
710 [450–5100] 1820 [315–3300] NS
.8 [2–5.9] 2.7 [1.5–5.8] NS
1/32 65.6 % 80/120 66.7 % NS
0/32 62.5 % 56/125 44.8 % 0.079
1/20 55,0 % 21/46 45,7 % NS
/32 15.6 % 39/125 31.2 % 0.081
.5 [0.8–6.1] 3.2 [1.5–6.9] NS
8/32 87.5 % 77/125 61.6 % 0.006
gan Dysfunction system, NS not significant
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for 7 (22 %) of them. In the 76 patients with a final diagno-
sis of pneumococcal meningitis, 20 (26 %) were treated
with rifampin. Two-thirds (n=13) of them received rifam-
pin within the first 24 h of hospital admission.
Patient demographics, severity at ICU admission, and
microbiological data did not differ between the patients
who did or did not receive rifampin. Corticosteroid therapy
was used more frequently in those who received rifampin.
A detailed comparison of these groups is shown in Table 1.
Rifampin was administered twice daily. Doses were
either 600 mg or 900 mg twice daily, depending on the
patient’s weight (about 10 mg/kg twice daily).
In the entire population (n=157), none of the patients
treated with early rifampin (within the first 24 h of
hospitalization) died. The difference in mortality reached
statistical significance only for patients with pneumococ-
cal infection. Indeed, among the latter 76 patients, none
of the 18 non-survivors were treated with early rifampin
(during the first 24 h of hospitalization), whereas 13 of
58 patients did receive early rifampin among the survivors
(p=0.031) (Table 2).
The GOS was also statistically associated with the use
of rifampin, with the rifampin-treated patients having a
statistically better GOS score than the others (Additional
file 1: Figures S2 and S3).
For the entire cohort, 10 antibiotic-related AEs were
reported (6 %). Two events were associated not with an-
tibiotics prescribed for the initial bacterial meningitis,
but with another prescription during the hospitalization.
Two AEs were related to vancomycin use (inflammation
at injection site). Six were reported with the use of a β-
lactam: abnormal liver tests (n=2), encephalopathy (n=1),
Clostridium difficile diarrhea (n=1), and oral candidiasis
(n=1). No AEs were reported for rifampin use.
Mortality-associated factors
Factors associated with ICU mortality were analyzed for
the whole population. The results of the univariateTable 2 Correlation between ICU mortality and rifampin treatment
Rifampin use Non-survivors
Entire population n=23
Rifampin during hospitalization 2/23
Rifampin during first 48 h of hospitalization 1/23
Rifampin during first 24 h of hospitalization 0/23
Streptococcus pneumoniae meningitis n=18
Rifampin during hospitalization 2/18
Rifampin during first 48 h of hospitalization 1/18
Rifampin during first 24 h of hospitalization 0/18
NS not significant
Data are proportions of patients. They were compared with Fisher’s exact test
p Values <0.1 are detailed. p Values <0.05 were considered significant (bold)analysis are summarized in Table 3. On the basis of the re-
sults of univariate analyzes, we aimed to build different lo-
gistic regression models in order to more accurately assess
whether treatment with rifampin was associated with
outcome. Demographic parameters, data on severity at
admission, and treatment data such as antibiotics and
corticosteroids were entered into the model. Possible
interactions between variables were also tested. The
variables were alternately added or removed from the
model to test how they acted on this model. Those vari-
ables were selected that allowed the highest likelihood
ratio. For the final logistic analysis, 11 variables were
kept in the model: pulmonary, renal, cardiovascular,
and hematologic failure; pneumococcal infection; early
antibiotic administration (<2 h) and early treatment
with rifampin (<24 h); corticosteroid administration;
age (>75 years) and sex; and immunosuppression. The
results are presented in Table 4. Specific results for
patients with pneumococcal meningitis are shown in
Additional file 1: Tables S1 and S2).
Discussion
In this report, we describe a cohort of 157 patients.
Meningeal infections are rare conditions. So, in the
present study, for five ICUs and during the study period,
these infections represented only 1.2 % of admissions
(among more than 20,000 admitted patients).
Patients’ baseline characteristics are coherent in terms
of severity. Some might be surprised by the high Glasgow
Coma Scale scores (median 11) or low SAPS II, but these
data are consistent with those reported in other series
[2, 4]. We must emphasize that, at admission, 80 % of
the patients met criteria for severe sepsis or septic
shock and that for nearly half of them mechanical ventila-
tion was required. A previous study included patients with
more severe illness. They had exclusively pneumococcal
meningitis [1].
From a microbiological point of view, our results are
not surprising. The two main causative bacteria are S.in critically ill patients admitted with bacterial meningitis
Survivors p Value
n=134
8.7 % 30/134 22.4 % NS
4.3 % 23/134 17.2 % NS
0.0 % 19/134 14.2 % 0.078
n=58
11.1 % 18/58 31.0 % NS
5.6 % 15/58 25.9 % 0.097
0.0 % 13/58 22.4 % 0.031
Table 3 Comparison of patient characteristics, severity at ICU admission, microbiological data, and therapeutic measures between
survivors and non-survivors after ICU admission for bacterial meningitis (n=157)
Characteristics Non-survivors Survivors p Value
n=23 n=134
Demographics IQR IQR
Age, yr 65 [40.6–74.3] 41 [28.7–59.1] 0.003
Female sex 4/23 17.4 % 56/134 41.8 % 0.035
Immunosuppression 9/23 39.1 % 20/134 14.9 % 0.016
Alcohol use disorder 7/23 30.4 % 11/132 8.3 % 0.007
Asplenia 2/23 8.7 % 4/133 3.0 % NS
HIV infection 3/23 13.0 % 5/133 3.8 % 0.096
Severity at ICU admission
Glasgow Coma Scale score 7 [4–9] 12 [9–15] <10−3
Mechanical ventilation 20/21 95.2 % 40/115 34.8 % 0.004
Severe sepsis or septic shock 21/21 100.0 % 94/115 81.7 % 0.043
SAPS II 64 [53–73] 27 [15–36] <10−3
LOD system
Neurologic 21/21 100.0 % 61/115 53.0 % <10−3
Pulmonary 20/21 95.2 % 40/115 34.8 % <10−3
Hematologic 12/21 57.1 % 45/115 39.1 % 0.151
Cardiovascular 12/21 57.1 % 38/115 33.0 % 0.048
Renal 13/21 61.9 % 19/115 16.5 % <10−3
Hepatic 0/21 0.0 % 0/115 0.0 % –
Microbiology
CSF white cell count/mm3 1900 [290–4500] 1770 [494–5050] NS
CSF protein rate, g/L 8.4 [4.7–10.6] 3.1 [1.8–4.9] <10−3
Positive direct examination of CSF 17/22 77.3 % 84/130 64.6 % NS
Streptococcus pneumoniae as causative bacterium 18/23 81.8 % 58/134 43.3 % 0.003
Penicillin non-susceptible isolates 7/14 31.8 % 25/52 48.1 % NS
Neisseria meningitidis as causative bacterium 1/23 4.5 % 43/134 32.1 % 0.005
Therapeutic measures
Time between hospital admission and first dose of antibiotic (h) 4 [1.9–8.5] 2.4 [0.7–6] 0.102
Association of antibiotics as initial therapy 22/23 95.7 % 97/134 72.4 % 0.016
Treatment with rifampin during the hospitalization 2/23 8.7 % 30/134 22.4 % 0.168
Early treatment with rifampin (within first 24 h) 0/23 0.0 % 19/134 14.2 % 0.078
Treatment with vancomycin during hospitalization 20/23 87.0 % 78/134 58.2 % 0.01
Early treatment with vancomycin (within first 24 h) 17/23 73.9 % 66/134 49.3 % 0.041
Treatment with corticosteroids during hospitalization 18/23 78.3 % 87/134 64.9 % NS
Time between hospital admission and first dose of corticosteroids (h) 8 [5–13] 5.4 [1.7–9.5] 0.042
SAPS II Simplified Acute Physiology Score II, CSF cerebrospinal fluid, LOD Logistic Organ Dysfunction system
Data are proportions of patients and percentages or median values [interquartile range]
p Values <0.2 are detailed. p Values <0.05 were considered significant (bold)
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typical of what is reported in the literature [5].
The originality of this work lies in the analysis of
rifampin use to treat bacterial meningitis. As discussed
in the Introduction, the years 2002–2005 appeared to be
marked by a change in prescriptions of antibiotics forbacterial meningitis in France. Our study confirms this
characterization. Thus, vancomycin prescriptions were
very common in 2004 and then fell sharply. The rise of
rifampin lies in the potentially very interesting properties
of the molecule. This drug has been known for a long
time [21]. It is widely used for tuberculosis and bone or
Table 4 Factors associated with ICU mortality in a cohort of 157
patients admitted for bacterial meningitis
Variable Odds ratio (95 % CI) p Value
Pulmonary failure 67.7 (3.7–1225.7) 0.004
Renal failure 12.6 (2.2–73.1) 0.005
Cardiovascular failure 9.8 (1.7–57.6) 0.012
Pneumococcal infection 9.0 (1.1–74.8) 0.042
Early antibiotic administration (<2 h) 0.3 (0.0–1.6) 0.155
Hematologic failure 3.6 (0.6–20.6) 0.156
Corticosteroid administration 4.1 (0.5–36.2) 0.200
Age (>75 yr) NS
Immunosuppression NS
Female sex NS
Early treatment with rifampin (<24 h) NS
Incomplete observations were excluded from the logistic analysis. The
presented final model had 134 observations entered and yielded the highest
likelihood ratio. Nagelkerke’s R2 was 0.69. The 11 presented variables were
those included in the final logistic model
p Values <0.2 are detailed. p Values <0.05 were considered significant (bold)
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used as chemoprophylaxis in close contacts with patients
with meningococcal meningitis. It indeed has very inter-
esting pharmacokinetic properties, particularly its cere-
bromeningeal distribution. This is facilitated by its
lipophilic properties and its low molecular weight [24, 25].
In addition, for S. pneumoniae, MICs to rifampin are
extremely low [26]. Resistance remains exceptional [27].
Moreover, unlike vancomycin, its distribution is unaffected
by the addition of corticosteroid therapy [10]. Based on
these attractive pharmacokinetic and pharmacodynamic
properties, animal studies have demonstrated the relevance
of this molecule for curative treatment of meningitis
[15, 28–31]. It could have a protective effect in limiting
inflammatory mediator release [32–37]. Reactive oxygen
species and matrix metalloproteases have both been
shown to contribute to brain damage [38–40]. Their pro-
duction could be limited by using non β-lactam antibiotics
[41]. For all these reasons and despite the lack of robust
data, clinicians have chosen to use this rifampin. Given
precisely the lack of data in the literature, it is interesting
to report on this clinical experience. However, our prelim-
inary data do not specify for which patients this treatment
would be the most beneficial. Our clinical view and pre-
clinical data suggest that, if effective, this treatment should
be administered early (in the very first hours) and in
patients with pneumococcal infection.
Our study also clarifies the factors associated with
ICU mortality. Thus, pneumococcal infections are again
identified as being associated with a worse outcome [1].
Our study shows that the patients with most severe ill-
ness at admission have the highest probability of death,
which is classic [42]. Shock is thus an independent riskfactor of mortality. In addition, we can specify that the
presence at admission of a respiratory or renal dysfunction
weighs heavily on the outcome. Neurological impairment
at admission is so common in this cohort that it does not
emerge as significantly associated with mortality in the
multivariate analysis. In contrast to previous studies, delay
in the first antibiotic administration or pneumococcal
phenotypes does not appear to be independently associ-
ated with mortality [43–45]. Precocity of antibiotic admin-
istration is indeed a cornerstone of the treatment for these
severe infections. Although they did not reach statistical
significance, our results confirm this fact. Concerning
non-susceptibility to penicillin, it had been associated with
mortality in a previous French study [45]. The latter could
weigh in favor of rifampin use because, even for penicillin
non-susceptible pneumococcal strains, MICs remain low
for this antibiotic. Our results might differ because of the
higher prevalence of penicillin non-susceptible S. pneumo-
niae (50 %) in comparison with the cited study (36 %).
However, our work has many limitations. The first is
that it included a small number of patients. Although
the cohort had a significant size, only 20 % of them
(n =32) were treated with rifampin. The number was
even smaller in the subgroup that received early treatment
(within the very first hours). However, this use of rifampin
has not been reported previously in humans. In addition,
new recommendations issued in late 2008 put an end to
the use of an antibiotic combination for bacterial meningi-
tis and promoted high doses of cephalosporin as mono-
therapy [46]. It was then not possible to extend the study
period.
The main limitation of the present study is its retro-
spective characteristic. We are indeed not able to explain
why clinicians have or have not chosen to administer
rifampin. Although we did not show significant major
differences between patients with or without rifampin,
the former more frequently received corticosteroids.
This may have played a role in the superiority of rifampin
versus no rifampin observed in the univariate analysis.
Nevertheless, we must not overestimate our results.
Whereas our univariate analysis shows a signal in favor
of a potential interest of rifampin use, multivariate ana-
lysis showed no association between ICU mortality and
rifampin use. Indeed, this study might be underpowered
related to the small size of the rifampin-treated patient
subgroup (n=32). It is true that multivariate analysis
does not show either link with corticosteroid use. How-
ever, for steroids in this study, it should be noted that
they were often administered as published by de Gans in
2002 [9] but sometimes differently. For instance, some
patients with septic shock have received low doses of
hydrocortisone instead of dexamethasone and hydrocor-
tisone on metabolic parameters (e.g., glucose and glu-
cose variability).
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emergence of resistant strains requires its use only in
combination therapy [22]. Although our study showed
good tolerance, this molecule can lead to significant AEs
[47]. Drug interactions require the cautious use of mul-
tiple therapies [48].
The interest in an association could be discussed. As
mentioned before, local recommendations in France
changed in late 2009. These actually stress the need for a
monotherapy with high doses of a third-generation ceph-
alosporin. However, owing to the versatile epidemiology of
pneumococcal infections and the mortality associated with
bacterial meningitis, new potential therapeutic data seem
welcome.
Conclusions
Our study presents a cohort of adult ICU patients and
specifically focuses on the use of rifampin in combination
with a third-generation cephalosporin to treat community-
acquired bacterial meningitis. This treatment could be of
interest for patients with S. pneumoniae infection, espe-
cially if administered early. Nevertheless, these results are
preliminary and can pave the way for further studies.
Key messages
 Rifampin in combination with a third-generation
cephalosporin is an option to treat community-
acquired bacterial meningitis.
 Such a treatment may reduce mortality in the ICU
(univariate analysis).
 Our study demonstrates that only four independent
factors were associated with ICU mortality:
pulmonary failure, renal failure, cardiovascular
failure, and pneumococcal infection.
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